全文获取类型
收费全文 | 311篇 |
免费 | 19篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 11篇 |
妇产科学 | 6篇 |
基础医学 | 37篇 |
口腔科学 | 5篇 |
临床医学 | 43篇 |
内科学 | 52篇 |
皮肤病学 | 14篇 |
神经病学 | 17篇 |
特种医学 | 4篇 |
外科学 | 29篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 42篇 |
眼科学 | 14篇 |
药学 | 21篇 |
中国医学 | 2篇 |
肿瘤学 | 28篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 15篇 |
2020年 | 8篇 |
2019年 | 6篇 |
2018年 | 21篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 13篇 |
2013年 | 17篇 |
2012年 | 25篇 |
2011年 | 33篇 |
2010年 | 17篇 |
2009年 | 11篇 |
2008年 | 19篇 |
2007年 | 21篇 |
2006年 | 9篇 |
2005年 | 6篇 |
2004年 | 12篇 |
2003年 | 8篇 |
2002年 | 12篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1978年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
1949年 | 1篇 |
1948年 | 2篇 |
1947年 | 1篇 |
1945年 | 1篇 |
1942年 | 3篇 |
1941年 | 1篇 |
1940年 | 3篇 |
1939年 | 1篇 |
1938年 | 2篇 |
1937年 | 1篇 |
1934年 | 1篇 |
1933年 | 1篇 |
1932年 | 1篇 |
1931年 | 3篇 |
1930年 | 1篇 |
1929年 | 1篇 |
1924年 | 2篇 |
1922年 | 1篇 |
1914年 | 1篇 |
排序方式: 共有330条查询结果,搜索用时 15 毫秒
1.
Immunohistochemical expression profiles of solute carrier transporters in alpha‐fetoprotein‐producing gastric cancer
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
4.
Yu Ueda PhD Satoru Takahashi MD PhD Naoki Ohno PhD Katsusuke Kyotani RT Hideaki Kawamitu MS Tosiaki Miyati PhD Nobukazu Aoyama RT Yoshiko Ueno MD PhD Kazuhiro Kitajima MD PhD Fumi Kawakami MD Tomoyuki Okuaki MS Ryuko Tsukamoto MT Emmy Yanagita MT Kazuro Sugimura MD PhD 《Journal of magnetic resonance imaging : JMRI》2016,43(1):138-148
5.
Shima Gholizadeh Emmy M. Dolman Rebecca Wieriks Rolf W. Sparidans Wim E. Hennink Robbert J. Kok 《Pharmaceutical research》2018,35(4):85
Purpose
Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys. The current study aims at improving the pharmacokinetic profile of YM155 by its formulation in immunoliposomes that can achieve its enhanced delivery into tumor tissue and facilitate uptake in neuroblastoma cancer cells.Methods
PEGylated YM155 loaded liposomes composed of DPPC, cholesterol and DSPE-PEG2000 were prepared via passive film-hydration and extrusion method. Targeted (i.e. immuno-)liposomes were prepared by surface functionalization with SATA modified monoclonal anti-disialoganglioside (GD2) antibodies. Liposomes were characterized based on their size, charge, antibody coupling and YM155 encapsulation efficiency, and stability. Flow cytometry analysis and confocal microscopy were performed on IMR32 and KCNR neuroblastoma cell lines. The efficacy of developed formulations were assessed by in-vitro toxicity assays. A pilot pharmacokinetic analysis was performed to assess plasma circulation and tumor accumulation profiles of the developed liposomal formulations.Results
YM155 loaded immunoliposomes had a size of 170 nm and zeta potential of ?10 mV, with an antibody coupling efficiency of 60% andYM155 encapsulation efficiency of14%. Targeted and control liposomal formulations were found to have similar YM155 release rates in a release medium containing 50% serum. An in-vitro toxicity study on KCNR cells showed less toxicity for immunoliposomes as compared to free YM155. In-vivo pharmacokinetic evaluation of YM155 liposomes showed prolonged blood circulation and significantly increased half-lives of liposomal YM155 in tumor tissue, as compared to a bolus injection of free YM155.Conclusions
YM155 loaded immunoliposomes were successfully formulated and characterized, and initial in-vivo results show their potential for improving the circulation time and tumor accumulation of YM155.6.
Geurt Stokman Yu Qin Tijmen H. Booij Sreenivasa Ramaiahgari Marie Lacombe M. Emmy M. Dolman Kim M.A. van Dorenmalen Gwendoline J.D. Teske Sandrine Florquin Frank Schwede Bob van de Water Robbert J. Kok Leo S. Price 《Journal of the American Society of Nephrology : JASN》2014,25(7):1474-1485
Activation of Rap1 by exchange protein activated by cAMP (Epac) promotes cell adhesion and actin cytoskeletal polarization. Pharmacologic activation of Epac-Rap signaling by the Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP during ischemia-reperfusion (IR) injury reduces renal failure and application of 8-pCPT-2′-O-Me-cAMP promotes renal cell survival during exposure to the nephrotoxicant cisplatin. Here, we found that activation of Epac by 8-pCPT-2′-O-Me-cAMP reduced production of reactive oxygen species during reoxygenation after hypoxia by decreasing mitochondrial superoxide production. Epac activation prevented disruption of tubular morphology during diethyl maleate–induced oxidative stress in an organotypic three-dimensional culture assay. In vivo renal targeting of 8-pCPT-2′-O-Me-cAMP to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged activation of Rap1 compared with nonconjugated 8-pCPT-2′-O-Me-cAMP. Activation of Epac reduced antioxidant signaling during IR injury and prevented tubular epithelial injury, apoptosis, and renal failure. Our data suggest that Epac1 decreases reactive oxygen species production by preventing mitochondrial superoxide formation during IR injury, thus limiting the degree of oxidative stress. These findings indicate a new role for activation of Epac as a therapeutic application in renal injury associated with oxidative stress.Renal ischemia-reperfusion (IR) injury is an important cause of AKI1 and a significant risk factor for the development of renal dysfunction after kidney transplantation.2 During IR injury, morphologic and functional alterations of the proximal tubular epithelium occur that are linked to the development of renal failure and activation of immune cells via release of proinflammatory cytokines.3Exchange protein activated by cAMP (Epac) is a guanine nucleotide exchange factor for the small GTPase Rap1.4 Activation of Epac by cAMP or by the Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP (also referred to as 007) induces functional activation of Rap1.5 Initial studies showed that Epac-Rap signaling enhances cell adhesion by supporting maturation of cell-cell junctions6,7 and promoting integrin-mediated cell-matrix adhesion.8,9 In line with these studies, we recently demonstrated that selective activation of Epac reduces proximal tubular epithelial cell (PTEC) detachment during IR injury using in vitro and in vivo models.10 Activation of Epac-Rap was associated with reduced expression of markers for cellular stress in PTECs. In addition, in vitro cisplatin-induced apoptosis of PTECs could be significantly reduced by activation of Epac and this was also associated with improved adhesion of cells.11 On the basis of these findings, we hypothesized that activation of Epac-Rap signaling may protect against a common cytotoxic event in these injury models.Unbalanced and uncontrolled production of reactive oxygen species (ROS) is an important mediator of cell injury and occurs during cisplatin nephrotoxicity,12 IR injury,13 and renal fibrosis.14 In renal pathology, intracellular ROS can be produced enzymatically such as by NADPH oxidase (NOX) complexes or derive from dysfunctional mitochondrial activity. Mitochondrial ROS production appears to be the driving force behind hypoxia-reoxygenation cell injury15 and cisplatin cytotoxicity.16Here we studied the role of specific proximal tubular activation of Epac and how this protects against renal injury in both in vitro and in vivo models for IR injury. We found that ROS production during reoxygenation after hypoxia was decreased by activation of Epac. Selective proximal tubular activation of Epac by renal targeting of 8-pCPT-2′-O-Me-cAMP conjugated to lysozyme (LZM-007) reduced oxidative stress in an in vivo model for IR injury and significantly decreased IR injury–associated renal failure and tubular damage. Our data show that Epac activation reduces ROS-mediated cellular injury in renal disease and may be a therapeutic strategy for modulation of oxidative stress. 相似文献
7.
Emmy Manders Harm-Jan Bogaard M. Louis Handoko Marielle C. van de Veerdonk Anne Keogh Nico Westerhof Ger J.M. Stienen Cristobal G. dos Remedios Marc Humbert Peter Dorfmüller Elie Fadel Christophe Guignabert Jolanda van der Velden Anton Vonk-Noordegraaf Frances S. de Man Coen A.C. Ottenheijm 《Journal of the American College of Cardiology》2014
Background
After lung transplantation, increased left ventricular (LV) filling can lead to LV failure, increasing the risk of post-operative complications and mortality. LV dysfunction in pulmonary arterial hypertension (PAH) is characterized by a reduced LV ejection fraction and impaired diastolic function.Objectives
The pathophysiology of LV dysfunction in PAH is incompletely understood. This study sought to assess the contribution of atrophy and contractility of cardiomyocytes to LV dysfunction in PAH patients.Methods
LV function was assessed by cardiac magnetic resonance imaging. In addition, LV biopsies were obtained in 9 PAH patients and 10 donors. The cross-sectional area (CSA) and force-generating capacity of isolated single cardiomyocytes was investigated.Results
Magnetic resonance imaging analysis revealed a significant reduction in LV ejection fraction in PAH patients, indicating a reduction in LV contractility. The CSA of LV cardiomyocytes of PAH patients was significantly reduced (∼30%), indicating LV cardiomyocyte atrophy. The maximal force-generating capacity, normalized to cardiomyocyte CSA, was significantly reduced (∼25%). Also, a reduction in the number of available myosin-based cross-bridges was found to cause the contractile weakness of cardiomyocytes. This finding was supported by protein analyses, which showed an ∼30% reduction in the myosin/actin ratio in cardiomyocytes from PAH patients. Finally, the phosphorylation level of sarcomeric proteins was reduced in PAH patients, which was accompanied by increased calcium sensitivity of force generation.Conclusions
The contractile function and the CSA of LV cardiomyocytes is substantially reduced in PAH patients. We propose that these changes contribute to the reduced in vivo contractility of the LV in PAH patients. 相似文献8.
9.
Andrea Beaton Emmy Okello Twalib Aliku Sulaiman Lubega Peter Lwabi Charles Mondo Robert McCarter Craig Sable 《Pediatric cardiology》2014,35(7):1259-1267
Screening with portable echocardiography has uncovered a large burden of latent rheumatic heart disease (RHD) among asymptomatic children in endemic regions, the significance of which remains unclear. This study aimed to determine the 2-year outcomes for children with latent RHD diagnosed by echocardiographic screening. Children identified with latent RHD enrolled in a biannual follow-up program. Risk factors for disease persistence and progression were examined. Of 62 children, 51 (82 %) with latent RHD had a median follow-up period of 25 months. Of these 51 children, 17 (33.3 %) reported an interval sore throat or symptoms consistent with acute rheumatic fever (ARF). Of 43 children initially classified as having borderline RHD, 21 (49 %) remained stable, 18 (42 %) improved (to no RHD) and 4 (10 %) worsened to definite RHD. Of the 8 children initially classified as having definite RHD, 6 (75 %) remained stable, and 2 (25 %) improved to borderline RHD. Two children had confirmed episodes of recurrent ARF, one of which represented the sole case of clinical worsening. The risk factors for disease persistence or progression included younger age (p = 0.05), higher antistreptolysin O titers at diagnosis (p = 0.05), and more morphologic valve abnormalities (p = 0.01). After 2 years, most of the children had a benign course, with 91 % remaining stable or showing improvement. Education may improve recognition of streptococcal sore throat. Longer-term follow-up evaluation, however, is warranted to confirm disease progression and risk factor profile. This could help tailor screening protocols for those at highest risk. 相似文献
10.